Background And Aims: Inflammatory Bowel Disease (IBD) are known to impact patients 'sexual lives. The aim of this study is to create and validate a sexual QoL designed for youth with IBD.
Methods: This study was conducted in two phases: development of the score and validation of the items. A multidisciplinary team created a score called BLOOMI, based on two validated scores: the International Index of Erectile Function (IIEF) and the Sexual Function Questionnaire 28 (SFQ28). It was validated through a French multicentric cross-sectional study among patients aged 15-25 years with IBD by comparison with IIEF and SFQ28 gold standard scores.
Results: BLOOMI is a sexual QoL designed with 10 items and formatted as a disk. The score was validated through the participation of 104 patients with a median age of 23.2 years. BLOOMI was well correlated with both goldstandards and had a strong internal consistency. 19.1% of IIEF-responders have erectile dysfunction and median scores for the SFQ domains Desire, Arousal sensation and cognition, and orgasm are below the threshold for the absence of sexual dysfunction. Fatigue, abdominal pain, body image concerns or fear of anal leakages are correlated to a poorer sexual QoL.
Conclusions: BLOOMI score is a new validated score to assess the sexual QoL in 15-25 years with IBD. This tool may improve the screening for sexual challenges encountered by youths with IBD and may support future research into the impact of IBD on young patients' lives.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/ecco-jcc/jjae175 | DOI Listing |
Aesthetic Plast Surg
January 2025
Division of Plastic Surgery, Department of Surgery, University of Pennsylvania Health System, PCAM South Pavilion 14th Floor, 3400 Civic Center Boulevard, Philadelphia, PA, 19104, USA.
Introduction: Breast reduction surgery addresses both functional complaints and aesthetic concerns. Two commonly used incision patterns in the US are the Wise and vertical patterns, but there are limited data comparing their clinical and quality of life (QoL) outcomes. This study evaluates and compares these outcomes between the two techniques.
View Article and Find Full Text PDFSoc Sci Med
December 2024
Gauteng City-Region Observatory, University of Johannesburg, University of the Witwatersrand, 11 Jorissen Street, Johannesburg, South Africa; School of Geographical Sciences, University of Bristol, University Road, Bristol, BS8 1SS, UK.
Background: South Africa's history of apartheid has led to persistent inequalities. While progress has been made since 1994, disparities in quality of life (QoL) remain, particularly along racial lines. This study examines how race, gender, and sexual orientation intersect to influence QoL in Gauteng - South Africa's most populous and economically vibrant province.
View Article and Find Full Text PDFTher Adv Musculoskelet Dis
December 2024
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, Windmill Road, Oxford OX3 7HE, UK.
Background: Psoriatic arthritis (PsA) is a chronic inflammatory condition that can affect individuals of all ages. Patients may experience a range of physical and psychological issues.
Objective: To examine the impact of PsA on an individual's quality of life (QoL) and physical function.
Adv Biomed Res
October 2024
Department of Psychiatry, Psychosomatic Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Background: This study aimed to compare the efficacy of the two antidepressants, duloxetine and bupropion, on pelvic pain in patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).
Materials And Methods: This single-blind clinical trial was conducted on 68 CP/CPPS patients. The patients with CP/CPPS received either an extended-release formulation of 150 mg/day bupropion (bupropion group) or duloxetine 30 mg/day for 12 weeks (duloxetine group).
Pulmonary arterial hypertension (PAH) is a chronic progressive exacerbation of cardiopulmonary vascular disease. The patients' exercise endurance decreased progressively and the survival rate was low. Current basic therapy and targeted drug therapy can improve the quality of life (QoL) of PAH patients, but the long-term efficacy and prognosis are not good.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!